Home   >  
Jak/Stat Pathway
  • Wnt/Stem Cell
  >  
Stat

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Stat

Chemical Structure Cat. No. Product Name CAS No.
STX-0119 Chemical Structure
BCP25956 STX-0119 851095-32-4
STX-0119 is a potent STAT3 inhibitor.
Niclosamide Chemical Structure
BCP22958 Niclosamide 50-65-7
Niclosamide is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide inhibits STAT3 with IC50 of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.
Brevilin A Chemical Structure
BCP30982 Brevilin A 16503-32-5
Brevilin A, is a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. antitumour
Golotimod Chemical Structure
BCP24651 Golotimod 229305-39-9
Golotimod is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production.
MDK-6314 Chemical Structure
BCP28976 MDK-6314 285986-31-4
MDK-6314 is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.
FLLL32 Chemical Structure
BCP28141 FLLL32 1226895-15-3
FLLL32, a novel curcumin analogue, is a potent STAT3 inhibitor.
Alantolactone Chemical Structure
BCP24288 Alantolactone 546-43-0
Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
SH-4-54 Chemical Structure
BCP28211 SH-4-54 1456632-40-8
SH-4-54 is a most potent, small molecule, nonphosphorylated STAT3 inhibitor, strongly binds to STAT3 protein (KD = 300 nM), is selective for STAT3 over STAT1.
HO-3867 Chemical Structure
BCP24295 HO-3867 1172133-28-6
HO-3867 a selective and potent inhibit STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.
Debio 0617B Chemical Structure
BCP25046 Debio 0617B 1332329-27-7
Debio 0617B has been developed as a first-in-class kinase inhibitor with a unique profile targeting phospho-STAT3 (pSTAT3) and/or pSTAT5 in tumors through combined inhibition of JAK, SRC, ABL, and class III/V receptor tyrosine kinases (RTK).
123下一页共 27 条记录 1 / 3 页 
0086-13720134139